Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies

Summary: Cross-presentation of tumor antigens represents a key pathway in antitumor immune responses that can be exploited to synergize not only with the already prominent “checkpoint blockade,” but also with newer attempts to use T-cell stimulatory monoclonal antibodies in immunotherapy. Cancer Discov; 6(1); 17–9. ©2016 AACR . See related article by Sanchez-Paulete et al., [p. 71][1] . [1]: /lookup/volpage/6/71?iss=1